A number of tricyclic acyclovir (ACV) and ganciclovir (GCV) derivatives substituted with bulky lipophilic groups have been identified as potent and highly selective cytostatic agents against herpes simplex virus type 1 (HSV-1)-thymidine kinase (TK) gene-transduced human osteosarcoma and murine mammary carcinoma tumor cells. Although their affinity for HSV-1 TK was inferior to that of ACV or GCV, their cytostatic potency and selectivity was at least as high as observed for the parental ACV and GCV compounds. The tricyclic ACV and GCV derivatives were also endowed with
Introduction
Exposure of tumor cells transduced by the herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) gene to the anti-herpetic drug ganciclovir (GCV) has been shown to result in selective killing of the tumor cells by this drug in cell culture and in mice that were inoculated with HSV-1 TK gene-transduced sarcoma cells and subsequently treated with GCV. 1, 2 This observation has led in 1992 to the successful in vivo application of ganciclovir by Culver and colleagues, who demonstrated that glioma tumor-bearing rats transfected in situ by the HSV-1 TK gene could be successfully treated with ganciclovir.
a very pronounced bystander effect in cell culture, albeit at relatively high drug concentrations. Unlike ACV and GCV, the tricyclic purine derivatives are endowed with intrinsically strong fluorescent properties, which allow simple and sensitive monitoring of drug concentrations in biological fluids and tissues. Also, the lipophilicity of the tricyclic purine derivatives is much higher than that of ACV and GCV, and this may allow better uptake of these derivatives from the blood into the central nervous system. Gene Therapy (2002) 9, 1173-1182. doi:10.1038/sj.gt.3301779 plasma and other biological materials in GCV-treated cancer patients would seem important to more reliably predict or optimize drug therapy. Recently, we designed a number of acyclovir and ganciclovir derivatives that are endowed with intrinsic strong fluorescent characteristics by synthesizing tricyclic ACV and GCV derivatives containing an additional aromatic entity attached to the purine system ( Figure 1) . 10 These tricyclic purine nucleoside analogues (TPNAs) turned out to be potent and selective anti-herpesvirus agents, several of which were as potent antiviral agents as the parental ACV and GCV (Ref. 10 and manuscript submitted). Encouraged by these observations, we also investigated these novel compounds for their potential to be used in the combined gene/chemotherapy of cancer cells transduced with the HSV-1 TK gene. We found that several tricyclic ACV and GCV derivatives had interesting properties that may make them attractive drug candidates to be further investigated from both a diagnostic (imaging) and therapeutic viewpoint.
Results

Antiviral and cytostatic activity of substituted tricyclic acyclovir derivatives
A variety of tricyclic acyclovir derivatives bearing several substituents on the third ring were synthesized ( Table 1) . The R 1 moiety usually consisted of a phenyl moiety con- (Table 1) . A variety of esters (ie 6-8) showed similar activity as the parent p-hydroxyphenyl derivative 5. Presumably, their biological activities are based on the release of the hydroxyphenyl derivative in the presence of extracellular and/or intracellular a-specific esterases.
The substituted amino derivatives 9 to 11 were less active. Also, the presence of a methoxy group on the phenyl ring at positions other than para, decreased the antiviral activity (12) (13) (14) .
When evaluated for their cytostatic activity against human osteosarcoma OST TK Ϫ and murine mammary carcinoma FM3A cells transduced with the HSV-1 TK gene, a similar structure-activity relationship was observed as for their antiviral activity ( Table 2 ). The most potent inhibitors of virus replication ranked also among the most potent inhibitors of tumor cell proliferation and were comparable in their cytostatic potency to acyclovir. Indeed, when the antiviral activity of the tricyclic ACV derivatives were plotted against their cytostatic activity against OST TK Ϫ /HSV-1 TK + cells, a fairly close correlation was witnessed (r = 0.77) (Figure 2a) . The compounds were much less effective in inhibiting the proliferation of untransduced OST TK Ϫ cells, pointing to the pivotal role of HSV-1 TK in mediating the cytostatic activity of the test compounds ( ) amounted up to 1000 for the most active congeners (ie compounds 5 and its acetyl ester derivative 6, but also the phenyl boric hydroxyde derivative 19 (SI: >1724)). Strikingly, the cytostatic activity noted for the test compounds against HSV-1 TK gene-transduced murine mammary carcinoma FM3A cells was much less pronounced (up to Ն100-fold) than that observed for the human OST TK Ϫ /HSV-1 TK + cells (Table 2 ). However, a close correlation between the cytostatic activity of the compounds against both HSV-1 TK gene-transduced cell lines (OST and FM3A) was found (r = 0.82) (data not shown), showing a similar trend of sensitizing human and murine tumor cells to the new compounds upon transduction by the HSV-1 TK gene.
Antiviral and cytostatic activity of substituted tricyclic ganciclovir derivatives
A variety of tricyclic ganciclovir derivatives bearing the most interesting substituents observed with the tricyclic acyclovir series were also synthesized and evaluated for their inhibitory activity against herpes simplex virus type 1 replication (Table 3) and HSV-1 TK gene-transduced tumor cell proliferation (Table 4) . A strikingly similar structure-activity relationship was found for the tricyclic GCV derivatives as previously noted for the ACV derivatives. However, in general, the most potent antiviral and cytostatic compounds among the tricyclic GCV series (ie compounds 25 and 26, as well as 27 and 28) were 10-to 50-fold more inhibitory and selective against HSV-1 replication and HSV-1 TK gene-transduced tumor cell proliferation than the corresponding tricyclic ACV derivatives. The most active compounds were endowed with a selectivity index (SI) of more than 100 000-fold, that is~100-fold higher than for the tricyclic ACV derivatives. Again, there was a close correlation between the anti-herpes and cytostatic (OST TK Ϫ /HSV-1 TK + ) activity of the tricyclic GCV derivatives (r = 0.77) (Figure 2b ), and there was also a close correlation between the cytostatic activity of the compounds against the HSV-1 TK genetransduced human osteosarcoma OST TK Ϫ and murine FM3A mammary carcinoma cells (r = 0.96) (data not shown). As observed for acyclovir, GCV was also 100-fold more cytostatic against the human tumor cells than the murine tumor cells. (Table 5) .
Metabolic conversion of [
There were striking differences in metabolic conversion of GCV and ACV in both cell types. The highest levels Gene Therapy of ACV-and GCV-triphosphates were obtained after 6 h and further steadily decreased after 24 and 48 h in murine FM3A TK Ϫ /HSV-1 TK + cells. However, the opposite phenomenon was observed in the human OST TK Ϫ /HSV-1 TK + cells, especially for GCV. In this cell line, GCV metabolites steadily accumulated in function of incubation time and reached their highest levels after 48 h (Table 5) . Moreover, GCV-TP and ACV-TP, the presumed active metabolites that cause the eventual cytostatic activity of these compounds, accumulated in the human cells at levels that were 200-to 4000-fold higher than in the murine cells. Also, GCV metabolites accumulated to 30-to 250-fold higher levels than ACV metabolites. The markedly different formation of the triphosphate derivatives of ACV and GCV in the murine and human tumor cell cultures also closely corresponded with the amount of ACV-and GCV-derived radiolabel incorporated into the methanol-insoluble material of both cell lines (Table 6) . Thus, our metabolic data provide an explanation for the superior cytostatic activity of GCV over ACV in both cell lines, as well as for the more potent cytostatic activity of GCV (and its tricyclic derivatives) against the human OST TK for 18 (IC 50 : 914 M), measurably inhibited the enzyme reaction at 1000 M. Whereas GCV inhibited the reaction at an IC 50 of 88 M, only 24 and 25 were measurably inhibitory (IC 50 : 513 and 685 M, respectively), albeit at a concentration that was~six-to eight-fold higher than GCV to afford 50% inhibition of the enzyme reaction. These data point to a certain loss of affinity of the HSV-1 TK enzyme for the majority of tricyclic ACV and GCV derivatives.
Bystander effect of tricyclic ACV and GCV derivatives
Acyclovir and ganciclovir are known to exert a prominent bystander effect contributing to their overall cytostatic activity against HSV-1 TK gene-transfected tumor cells in vivo. We were able to visualize the bystander effect of ACV and GCV by the MTT dye viability method by exposing high drug concentrations to various mixtures of HSV-1 TK gene-transduced OST/TK Ϫ cells and untransduced OST/TK Ϫ cells at different ratios of both cell lines. The drug concentrations at which a pronounced bystander effect was observed were several orders of magnitude higher than their IC 50 values. We compared the inhibitory potential of the drugs with the theoretically calculated cytostatic values that are expected when no bystander effect is assumed. As shown in Figure 3a and b, both ACV and GCV exhibited a pronounced bystander effect in the mixed tumor cell cultures at several drug concentrations. Interestingly, the tricyclic GCV derivatives 23 and 26 (Figure 4c and d) and the tricyclic ACV derivative 4 ( Figure 4b ) showed a bystander effect that was at least as efficient as that of the parental GCV and ACV compounds. The tricyclic ACV derivative 3, which was less cytostatic than ACV, also showed a lesser prominent bystander activity in the mixed tumor cell cultures than ACV (Figure 4a ). It should be noticed that the concentrations at which the bystander effect of ACV and its tricyclic derivatives were evaluated invariably ranged between 10-to 1000-fold their cytostatic activity in cell culture. The ratios of drug concentrations used for measuring the bystander effect of GCV and its derivatives were 100-to 400 000-fold their cytostatic activity. However, high drug concentrations were required to afford measurable cellular toxicity within 3 days. The most efficient derivatives were endowed with a bystander effect at concentrations that were comparable to those of ACV or GCV to afford an equally potent bystander effect in cell culture. Intriguingly, in virtually all cases, viability of the cells was higher than expected at the higher percentages of HSV-1 TK gene-transduced cells in the cell mixture experiments. The reason for this phenomenon is currently unclear, but it should be emphasized that the bystander effect is most pronounced and evident at HSV-1 TK gene-transduced/non-transduced cell ratios at which the majority of cells in the mixtures were non- 
Lipophilicity of ACV, GCV and tricyclic ACV and GCV derivatives
An estimate of the lipophilicity was made for ACV, GCV and a variety of TPNAs by examining their retention times on a reverse phase column by HPLC analysis and by determination of the partition coefficient of the drugs between n-octanol and PBS. Both assays correlated very well. The correlation coefficients (r) between the retention Gene Therapy time on the reverse phase HPLC column and the log of the partition coefficient were as high as 0.967 and 0.986, respectively, for the tricyclic GCV and ACV derivatives ( Figure 5 ). ACV and GCV were the most polar compounds followed by the unsubstituted tricyclic ACV and GCV derivatives (compounds 1 and 21) . The phenyl-substituted tricyclic ACV (3) (4) (5) (6) (7) 13) and GCV (21, 23-26) derivatives were at least two to three orders of magnitude more lipophilic than ACV and GCV. In particular, the phenyl-substituted and methoxyphenyl-substituted tricyclic ACV (4, 13) and GCV (24, 33) derivatives emerged as among the most lipophilic drugs evaluated in this study ( Figure 5 ). 
UV and fluorescence spectrum of tricyclic ACV and GCV derivatives
The UV and fluorescence spectra of 5 and 1 nmole of several tricyclic ACV and GCV derivatives were determined at their optimal wavelength by applying the compounds on a reverse phase column of an HPLC apparatus equipped with both a UV and a fluorescence detector. The peak areas of the different TPNAs were determined and the ratio of the fluorescence peaks of the novel tricyclic ACV and GCV derivatives to the area of the UV peak of the parent ACV or GCV were calculated (Table  7) . Ratios higher than 1 reflect an increased sensitivity of fluorescent detection of the tricyclic ACV and GCV derivatives compared with UV detection of ACV and GCV, respectively, and thus may give an estimate of the increased detection limit of the fluorescent tricyclic GCV and ACV derivatives versus the parental ACV and GCV. As a rule, the fluorescent tricyclic GCV and ACV analogues could be detected at lower drug levels than GCV or ACV (Table 7) . Therefore, it can be assumed that some of the fluorescent TPNAs enable fluorescence-based detection in biological fluids and tissues (ie plasma, central nervous system (CNS)) that is markedly higher (greater than one order of magnitude) than the conventional UV-based ACV and GCV detection methods.
Discussion
The current GCV-based therapeutic approaches towards cancer (cells) that are transduced by the herpes simplex virus type 1 thymidine kinase gene are suboptimal and need to be improved. Drawbacks of GCV are its limited penetration in the brain and the CNS compartment 11 and toxic side-effects when administered systemically. Also, efficient monitoring of plasma levels of GCV is of crucial importance to enable optimal drug treatment for the individual patients. The tricyclic GCV and ACV derivatives described in this study fulfil these two criteria for more optimised treatment. They preserve the antitumor (cytostatic) potential and pronounced bystander effects of GCV (and ACV) (albeit at relatively high drug concentrations) but are, in addition, substantially more lipophilic than GCV and ACV. Although the most cytostatic tricyclic GCV and ACV derivatives (ie compounds 25 and 5) are not the most lipophilic compounds evaluated in this study, they are at least 100-fold more lipophilic than the parental GCV and ACV derivatives as measured by their partition coefficient between noctanol/H 2 O. Also, several tricyclic GCV or ACV analogues can now be detected in biological fluids at drug concentrations that are markedly lower than GCV (or ACV) based on their intrinsic fluorescent properties. Moreover, other UV absorbing, non-fluorescent plasma constituents do not interfere with the fluorescence-based drug detection and quantification, which makes the monitoring of the TPNAs simple, more straightforward and more sensitive and reliable than for the parental compounds GCV or ACV.
The molecular interaction of ganciclovir and acyclovir with the herpetic thymidine kinase is well known and based on the crystallographic structure of the enzyme complexed with the antiherpetic drugs. In these structures, it can be seen that GCV and ACV are located in the substrate (dThd)-binding pocket of the enzyme, and that the purine ring of GCV and ACV partially overlaps with the pyrimidine ring of dThd. Both purine and pyrimidine rings are positioned between Tyr-172 and Met-128, and form two hydrogen bonds with Gln-125. 12 However, when the phenyl-substituted tricyclic purine ring of the TPNAs is modeled in the HSV-1 TK substrate pocket, keeping the acyclic aliphatic side chain fixed, there is no space available to accommodate the third cyclic ring together with the additional phenyl ring. Therefore, it is very surprising that the tricyclic purine nucleoside analogues fit in the substrate binding pocket of the enzyme. These findings could not be anticipated from any crystal structure of HSV-1 TK with purine and pyrimidine nucleoside substrates reported thus far, 12 but it seems clear that there must exist a lipophilic pocket to efficiently host the substituted phenyl moiety on the tricyclic ACV and GCV ring systems.
We have unambiguously shown that HSV-1 TK is obligatory for activating (phosphorylating) the novel Tables 1 and 3. drugs as antiherpetic or cytostatic agents, since TKdeficient HSV-1 strains are not inhibited by these drugs and tumor cells that are not expressing HSV-1 TK are not sensitive to the cytostatic activity of these compounds. Also, we have shown that compounds 4, 24 and 25 are efficiently converted to their triphosphate derivatives when exposed to purified HSV-1 TK in a reaction mixture also containing purified GMP kinase and NDP kinase (data not shown). Thus, there is no doubt that HSV-1 TK (and several cellular enzymes of purine nucleotide metabolism) are able to recognize the TPNAs as a substrate for phosphorylation, although HSV-1 TK recognizes the tricyclic purine nucleoside analogues of GCV and ACV less efficiently as a substrate than the parental compounds GCV and ACV, respectively. It is interesting to note that the cytostatic activity of both tricyclic ACV and GCV group of compounds against HSV-1 TK genetransduced tumor cells highly correlated with their antiherpes simplex virus activity in cell culture (Figure 2 ). This means that the eventual target for cytostatic activity of these compounds (eg presumably cellular DNA polymerase(s)) must have a comparable structureactivity relationship for the tricyclic ACV and GCV derivatives as the viral DNA polymerase which is the eventual target for antiviral activity of these compounds in virus-infected cells. This also means that interesting cytostatic tricyclic ACV or GCV candidate compounds potentially useful for HSV-1 TK gene-based chemotherapy of cancer can be selected from a primary antiherpetic screen of these compounds. Since the most Table 7 Sensitivity of detection of tricyclic ACV and GCV derivatives by their optimal UV and fluorescence spectrum efficient cytostatic TPNAs exert a cytostatic potential and bystander effect (at relatively high drug concentrations) that are at least comparable to those found for the parental drugs GCV and ACV, the TPNAs described here should be regarded as a novel class of unusual purinebased nucleoside analogues who are able to fit into a unique TPNA-characteristic binding pocket in HSV-1 TK. Co-crystallization of TPNAs with HSV-1 TK is currently ongoing to better understand the molecular interaction of these drugs with HSV-1 TK and to rationally optimize the compound structure for its interaction with the enzyme and its eventual cytostatic activity in HSV-1 TK gene-transduced tumor cells.
In conclusion, an entirely new class of unusual tricyclic purine nucleoside analogues have been discovered. The new compounds are at least as potent and efficient in their cytostatic activity as GCV and ACV against HSV-1 TK gene-transduced tumor cells. They have several additional advantages such as pronounced lipophilicity and intrinsic fluorescent characteristics that make them attractive new lead compounds to be used, from both a diagnostic (imaging) and therapeutic viewpoint, in the combined gene/chemotherapy of cancer.
Materials and methods
Test compounds
The tricyclic acyclovir and ganciclovir derivatives were synthesized as described (Ref. 10 and manuscript in preparation).
[CH 3 -3 H]dThd (radiospecificity: 65 Ci/mmole), [2, H]GCV (radiospecificity: 14.6 Ci/mmole) and [2,8- 3 H]ACV (radiospecificity: 8.6 Ci/mmole) were obtained from Moravek Biochemicals (Brea, CA, USA).
Cells
Establishment of murine mammary FM3A and human osteosarcoma 143B OST TK Ϫ cells deficient in cytosolic TK and transduced by the HSV-1 TK gene has been described previously. [13] [14] [15] The HSV-1 TK gene-transduced cells and their parental cell lines were cultivated in RPMI-1640 medium, supplemented with 10% fetal calf serum, 2 mM L-glutamine and 0.075% NaHCO 3 , in a humidified CO 2 -controlled incubator at 37°C.
Anti-herpes simplex virus type 1 assay
The anti-HSV-1 assays were based on inhibition of virusinduced cytopathicity in human E 6 SM fibroblasts following previously established procedures. 16 Briefly, confluent cell cultures in 96-well microtiter plates were inoculated with 100 CCID 50 of virus, 1 CCID 50 being the virus dose required to infect 50% of virus-inoculated cell cultures. After a 1-h virus adsorption period, residual virus was removed, and the cell cultures were incubated in the presence of two-to five-fold dilutions of the test compounds. Viral cytopathicity was recorded as soon as it reached completion in the control (drug-free) virusinfected cell cultures (at day 3 after infection).
Cytostatic activity assays
To evaluate the cytostatic activity of the test compounds against OST TK After 2 days (FM3A) or 3 days (OST) the FM3A cells and the OST cells (after being detached with trypsin solution (Gibco)) were counted in a Coulter counter (Coulter Electronics,, Harpenden, UK). The IC 50 was defined as the drug concentration required to inhibit cell proliferation by 50%.
Bystander effect assay
The procedure to evaluate the bystander effect of the compounds was modified from Park et al 18 as follows. OST TK Ϫ cells were mixed with HSV-1 TK-GFP genetransfected OST TK Ϫ cells in percentages ranging from 0 to 100% (0, 0.2, 1, 5, 10, 25, 50, 75, 90 and 100%) transfected cells. From these cell mixtures, 8400 cells/well were plated in 96-well microtiter plates (Falcon) and grown for 24 h at 37°C in a humidified CO 2 -controlled atmosphere. Growth medium containing 2% heat-inactivated fetal calf serum (FCS) was used. Cell mixtures were subsequently incubated in the presence of five-fold dilutions (in 2% FCS-containing medium) of the test compounds. After 3 days, ie the time needed for the untreated cell cultures to reach confluency, the viable cell number was assessed using the Cell Titer 96 Aqueous Non-radioactive MTT Cell Proliferation Assay (Promega, Madison, WI, USA). After 2.5-h incubation at 37°C, absorbance was measured by an ELISA reader at 490 nm. It was ascertained that absorbance increased linearly with increasing cell number, as monitored by a Coulter counter. 
